

FMHL/SEC/SE/Q3/BM/FEB'16

February 1, 2016

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 523696
Sub: Outcome of the Board Meeting

Dear Sir

This is to inform you that the Board of Directors of the Company at their meeting held today i.e. February 1, 2016, *inter-alia*, considered and approved Unaudited Financial Results of the Company for the quarter and period ended on December 31, 2015.


Please find enclosed 'Un-audited Financial Results' of the Company and 'Limited Review Report' thereon for the quarter and period ended December 31, 2015 alongwith a copy of the Press release being issued in this regard.

Further, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that Mr. Karthik Rajagopal, Non-Executive Non-Independent Director has resigned from the Boards of the Company w.e.f. February 1, 2016, due to his personal commitments.

This is for your information and records please.

Thanking you
Yours faithfully

For Fortis Malar Hospitals Limited


Sumit Goel
Company Secretary
FCS 6661



Encl: As above

FORTIS MALAR HOSPITALS LIMITED

Regd. Office: Fortis Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025
Tel: +91 11 2682 5000, Fax: +91 11 4162 8435, CIN: LB5110DL19B9PLC276986

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF
FORTIS MALAR HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Fortis Malar Hospitals Limited ("the Company") for the Quarter and Nine Months ended 31 December 2015 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Chennai, 1 February 2016
PS/EKP&MS/2016





Sriraman Parthasarathy
(Membership No. 206834)

FORTIS MALAR HOSPITALS LIMITED (CIN: L65110DL1989PLC276886)
 Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2015

Particulars	Standalone Quarter ended			Standalone Nine Months ended			Standalone year ended
	December 31, 2015	September 30, 2015	December 31, 2014	December 31, 2015	December 31, 2014	December 31, 2014	March 31, 2015
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(Audited)
1							
Income from Operations	3,310.36	3,294.01	3,075.10	9,610.25	8,684.35	8,684.35	11,763.92
a) Income from Operations	1.60	1.64	15.68	5.96	62.04	62.04	28.65
b) Other Operating income	3,311.96	3,295.65	3,090.78	9,616.21	8,746.39	8,746.39	11,792.57
Net Income from Operations							
2							
Expenses							
a) Drugs and Consumables	704.60	681.10	710.92	2,093.30	2,037.83	2,037.83	2,755.35
b) Employees Benefit Expenses	416.81	438.04	404.03	1,263.06	1,164.94	1,164.94	1,547.42
c) Professional Charges to Doctors	845.65	836.54	776.22	2,408.88	2,177.29	2,177.29	2,954.38
d) Clinical Establishment Fees	487.26	466.67	451.49	1,408.72	1,313.31	1,313.31	1,762.34
e) Depreciation and amortization Expenses	79.64	78.54	67.57	236.54	195.73	195.73	271.18
f) Other Expenses	708.77	652.65	528.23	1,939.44	1,538.15	1,538.15	2,020.35
Total Expenses	3,242.73	3,153.54	2,938.46	9,350.94	8,427.25	8,427.25	11,311.02
3							
Profit from operations before other income, finance costs & exceptional items (1-2)	69.23	142.11	152.32	265.27	319.14	319.14	481.55
4							
Other Income	186.38	189.18	185.49	576.26	548.78	548.78	736.41
5							
Profit before Finance Costs & Exceptional Items (3 + 4)	255.61	331.29	337.81	841.53	867.92	867.92	1,217.96
6							
Finance Cost	10.26	9.95	10.14	29.40	41.57	41.57	50.88
7							
Profit after Finance costs but before Exceptional items and Tax (5 - 6)	245.35	321.34	327.67	812.13	826.35	826.35	1,167.08
8							
Exceptional Items (Refer Note 4)	51.15	51.15	51.15	151.15	151.15	151.15	151.15
9							
Profit from Ordinary Activities before Tax (7 - 8)	194.20	321.34	327.67	760.98	826.35	826.35	1,167.08
10							
Tax expense	67.21	111.50	111.39	263.36	264.63	264.63	401.14
11							
Net Profit from Ordinary Activities After Tax	126.99	209.84	216.28	497.62	541.72	541.72	765.94
12							
Extraordinary items	126.99	209.84	216.28	497.62	541.72	541.72	765.94
13							
Net Profit for the Period / Year	1,861.70	1,860.95	1,860.95	1,861.70	1,860.95	1,860.95	1,860.95
14							
Paid up Equity Share Capital (Face Value Rs. 10 each)							
15							
Reserves excluding Revaluation Reserves							
16							
Earnings Per Share (EPS) (of Rs. 10 each not annualised)							
- Basic	0.68	1.13	1.16	2.67	2.91	2.91	4.12
- Diluted	0.68	1.13	1.16	2.67	2.91	2.91	4.10
17							
Dividend per Share (Face value of Rs. 10 each)							
- Final Dividend on equity shares (in Rs. per share)							0.50

- Notes:**
- The above unaudited standalone financial results have been reviewed by the Audit and Risk Management Committee, approved and taken on record by the Board of Directors in their meeting held on February 1, 2016 and have been subjected to a limited review by the Statutory Auditors of the Company.
 - The Company has identified business segment which is "Health Care Services" as its primary segment and geographic segment as its secondary segment. The amounts appearing in the results relate to this primary segment.
 - During the quarter ended December 31, 2015, 7,500 Equity Shares of Rs. 10 each at a premium of Rs. 16.20 each were allotted to eligible employees under the Company's Employees Stock Option Scheme (ESOP). The total outstanding employee stock options as at December 31, 2015 is 222,500.
 - Exceptional item for the period ended December 31, 2015 amounting to Rs. 51.15 Lakhs represents provision made by the Company for Additional Bonus pursuant to the amendment in the Payment of Bonus Act, 1965.
 - Previous period figures have been regrouped / reclassified, wherever necessary, to conform with the current period presentation.



By Order of the Board
 For and on Behalf of Board of Directors

 Raghunath, P
 Whole Time Director

Place: Chennai
 Date: February 1, 2016

PRESS RELEASE


**FORTIS MALAR REPORTS Q3FY16 REVENUE AT RS.33.12 CR, +7%
OPERATING PROFIT AT RS 1.71 CR
NET PROFIT AT RS 1.75 CR**

Chennai, Feb 1, 2016: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter and nine months ended December 31, 2015.

Commenting on the results Mr Daljit Singh, Chairman, Fortis Malar Hospitals Limited, Chennai, said, "Q3 has been a challenging quarter for the company, with incessant rain having disrupted life in the city. In spite of the challenges, our team of doctors, paramedics and administrative staff showed tremendous grit in maintaining inpatient services through this chaotic period. Even-though operations were seriously hampered, we have continued to see a consistent growth in revenues over the last 3 quarters. Our attention is now directed at improving occupancies and margins. I am also pleased to share that we have been rated amongst the top 3 hospitals in Chennai by The Week –Nielsen survey, underscoring our position as a leading tertiary care service provider in the region".

Financial Highlights for the Quarter (Q3FY2016)

- Fortis Malar Hospitals reported operating revenue of Rs 33.12 Cr compared to Rs 30.91 Cr, a growth of 7% over the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs 1.71 Cr compared to Rs. 2.20 Cr, in the corresponding quarter of the previous year.
- Net profit was at Rs 1.75 Cr compared to Rs.2.16 Cr, in the corresponding period, last fiscal.
- During the quarter, Fortis Malar witnessed growth in its key specialties, showing a markedly better performance in Cardiology, Urology and Neurology which grew by 21%, 14% and 79% respectively, as compared to the corresponding quarter of the previous year.



Financial Highlights for the YTD (9MFY16)

- For the nine months period ending December 2015, Fortis Malar Hospitals reported an operating revenue of Rs 96.16 Cr compared to Rs 87.46 Cr, a growth of 10% over the corresponding period of the previous year.
- Operating profit for the period stood at Rs 5.25 Cr compared to Rs. 5.15 Cr reported during the corresponding period of the previous year.
- Net profit was at Rs 5.46 Cr compared to Rs.5.42 Cr reported in the corresponding period of last fiscal.

Operational Highlights for the quarter


- Fortis Malar sets a new benchmark in emergency response standards by transporting a heart from Vellore to Chennai for the first time in a Chopper. This is a first in India and required meticulous planning.
- The expert medical team at the hospital continued to perform high risk and rare surgeries. During the quarter, the team performed the following complex surgeries:
- Doctors at Fortis Malar Hospitals Chennai braved heavy rain and huge traffic snarls to perform a heart transplant saving the life of a 47 year old patient.
- The Cardiology team at Fortis Malar successfully completed 64 heart transplants & 5 Lung Transplants during the first three quarters of the year..
- Fortis Malar was Ranked 3rd in the best multispecialty hospital category in Tamil Nadu in The Week-Nielsen Survey 2015.
- During the quarter, Fortis Malar launched the “Fortis-Gem Center For Obesity & Diabetes Management ”
- 17 Knee & 6 HIP Replacement were also performed at the hospital during the quarter.

Corporate Social Responsibility

Fortis Malar once again set a fine example in managing desperate situations by extending its humanitarian efforts to help the flood hit in Chennai. A massive disaster relief initiative was rolled out under the aegis of the SEWA programme run by the Fortis Foundation which also provided funds for medicines and medical consumables along with logistical support. Volunteers from Fortis hospitals in Chennai- Fortis Malar and Fortis Arcot Road reached out to over 1500 people in waterlogged areas through mobile medical camps, arranged free shelter for many of them within the hospital premises, treated police personnel who were participating in the relief effort and conducted vaccination camps for municipality staff who were helping with the cleanup operations in the city.

Playing its part as a good corporate citizen, Fortis Malar has been involved in meaningful community activities. It organized:

- Health awareness talks, Health checkups and free cardiac camps at various corporate and Government organizations.
- On the occasion of “World Stroke Day” Fortis Malar organized a press conference on the theme “PREVENT A STROKE BEFORE IT STRIKES YOU” which was attended by renowned Doctors and Stroke Survivors.
- Provided Free CPR training sessions as part of the Heart saver program at the hospital and at various corporates.
- As part of its Community Connect initiative - “Sunday Conversations” were organized with specialists from Fortis Malar on topical health issues.



About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.


Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 300 diagnostic centres.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.



Press Release



FOR MORE INFORMATION PLEASE CONTACT

Mr Venkata Ramanan D
PR & Communications
Fortis Malar Hospitals Ltd
Mobile: 8939831212
Venkata.ramanan@fortishealthcare.com

Sumit Jain
K2 Communications Pvt Ltd
Mobile: 9886021715
Sumit.jain@k2communications.in